title: Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity.
abstract: OBJECTIVE
  Overfeeding increases adipose tissue mass and leptin production and up-regulates the renin-angiotensin system in adipose tissue in rodents. Here, we determined the effect of chronic treatment with the renin inhibitor, aliskiren, in a model of diet-induced obesity in mice, on: (i) body weight, adipose tissue weight and plasma leptin; (ii) food intake and caloric efficiency; and (iii) angiotensin II (Ang II) in adipose tissue.
  
  
  METHODS
  Four-week-old C57BL/6J mice (n= 40) received aliskiren (50 mg.kg(-1).day(-1); 6 weeks) by means of a subcutaneous osmotic Alzet minipump. Animals were given either a low-fat (10% kcal from fat) or a high-fat diet (45% kcal from fat) during this period. Food-intake and body-weight variation were monitored during treatment.
  
  
  RESULTS
  In addition to a decrease of plasma renin activity, aliskiren reduced body-weight gain, adipose pads and plasma leptin concentration, independent of the diet. In adipose tissue, local concentrations of Ang II were also reduced by aliskiren.
  
  
  CONCLUSIONS
  Aliskiren limited the gain of adiposity in young mice. This effect was not due to changes in food intake or caloric efficiency and might be related to a down-regulation of the local renin-angiotensin system in adipose tissue. These effects were accompanied by reduced plasma leptin levels. As Ang II favours differentiation of adipocytes, it is possible that the decreased adipose tissue was linked to changes in adipocyte size and number.
authors.affiliation: Instituto Pluridisciplinar and Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
authors.forename: Paula
authors.initials: P
authors.lastname: Stucchi
authors.forename: Victoria
authors.initials: V
authors.lastname: Cano
authors.forename: Mariano
authors.initials: M
authors.lastname: Ruiz-Gayo
authors.forename: María S
authors.initials: MS
authors.lastname: Fernández-Alfonso
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D050154:Adiposity / Q000187:drug effects*; D000577:Amides / Q000494:pharmacology*; D000818:Animals; D004041:Dietary Fats / Q000008:administration & dosage*; D004435:Eating / Q000187:drug effects; D002149:Energy Intake / Q000187:drug effects; D005650:Fumarates / Q000494:pharmacology*; D020738:Leptin / Q000097:blood* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D009929:Organ Size / Q000187:drug effects; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects*; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D004041:Dietary Fats; D005650:Fumarates; D020738:Leptin; D012083:Renin; D000092502:Renin Inhibitors; C446481:aliskiren
references.citation: FASEB J. 2001 Dec;15(14):2727-9
references.pmid: 11606482
references.citation: Cell Metab. 2007 Dec;6(6):506-12
references.pmid: 18054319
references.citation: Endocrinology. 2003 Dec;144(12):5159-65
references.pmid: 12960011
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:119-46
references.pmid: 15822173
references.citation: Regul Pept. 1993 Jan 22;43(1-2):1-20
references.pmid: 8426906
references.citation: Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E91-5
references.pmid: 17374699
references.citation: Diabetes. 2005 Apr;54(4):991-9
references.pmid: 15793237
references.citation: Endocrinology. 2007 Mar;148(3):921-3
references.pmid: 17303671
references.citation: Endocrinology. 2004 Jan;145(1):169-74
references.pmid: 14512436
references.citation: Am J Physiol. 1997 Jul;273(1 Pt 2):R236-42
references.pmid: 9249555
references.citation: Lancet. 2006 Oct 21;368(9545):1449-56
references.pmid: 17055947
references.citation: J Gerontol A Biol Sci Med Sci. 1995 Sep;50(5):B270-6
references.pmid: 7671018
references.citation: J Hypertens. 1999 Apr;17(4):555-60
references.pmid: 10404958
references.citation: J Clin Endocrinol Metab. 1974 Nov;39(5):816-25
references.pmid: 4370699
references.citation: J Endocrinol. 2008 Apr;197(1):55-64
references.pmid: 18372232
references.citation: Endocrinology. 1994 Nov;135(5):2030-6
references.pmid: 7956925
references.citation: J Biomed Biotechnol. 2006;2006(5):27012
references.pmid: 17489015
references.citation: J Hypertens. 2002 May;20(5):965-73
references.pmid: 12011658
references.citation: Circ Res. 1988 Jun;62(6):1259-62
references.pmid: 3383369
references.citation: Hypertension. 2004 May;43(5):993-1002
references.pmid: 15007034
references.citation: Hypertension. 2007 May;49(5):1047-55
references.pmid: 17353513
references.citation: J Nutr. 2002 Jun;132(6):1135-40
references.pmid: 12042422
references.citation: Endocrinology. 2001 Jan;142(1):487-92
references.pmid: 11145613
references.citation: Eur J Pharmacol. 2008 Jul 7;588(2-3):316-24
references.pmid: 18501344
references.citation: Am J Hypertens. 1991 Jul;4(7 Pt 1):602-9
references.pmid: 1873015
references.citation: Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705
references.pmid: 12927775
references.citation: Hypertension. 2006 Jul;48(1):51-7
references.pmid: 16717145
references.citation: Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R943-9
references.pmid: 15191907
references.citation: Int J Biochem Cell Biol. 2003 Jun;35(6):807-25
references.pmid: 12676168
references.citation: Diabetes. 2002 Jun;51(6):1699-707
references.pmid: 12031955
references.citation: Physiol Rev. 2006 Jul;86(3):747-803
references.pmid: 16816138
references.citation: Endocrinology. 2005 Aug;146(8):3481-9
references.pmid: 15878965
references.citation: Endocrinology. 2007 Mar;148(3):924-31
references.pmid: 17082258